News
A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...
A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...
Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...
Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...
Online communities dedicated to the use of a toxic bleach solution to treat everything from cancer to autism believe Robert F ...
7h
24/7 Wall St. on MSNVisa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...
Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results